Heart Failure Research Center, Department of Cardiology and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
Circ Arrhythm Electrophysiol. 2011 Jun;4(3):262-70. doi: 10.1161/CIRCEP.111.961862. Epub 2011 Apr 14.
BACKGROUND: Thoracoscopic pulmonary vein isolation (PVI) and ganglionated plexus ablation is a novel approach in the treatment of atrial fibrillation (AF). We hypothesize that meticulous electrophysiological confirmation of PVI results in fewer recurrences of AF during follow-up. METHODS AND RESULTS: Surgery was performed through 3 ports bilaterally. Ganglionated plexi were localized and subsequently ablated. PVI was performed and entry and exit block was confirmed. Additional left atrial ablation lines were created and conduction block verified in patients with nonparoxysmal AF. The left atrial appendage was removed. Freedom of AF was assessed by ECGs and Holter monitoring every 3 months or during symptoms of arrhythmia. Antiarrhythmic drugs were discontinued after 3 months and oral anticoagulants were discontinued according to the guidelines. Thirty-one patients were treated (16 paroxysmal AF, 13 persistent AF, 2 long-standing persistent AF). Thirteen patients with nonparoxysmal received additional left atrial ablation lines. After 1 year, 19 of 22 patients (86%) had no recurrences of AF, atrial flutter, or atrial tachycardia and were not using antiarrhythmic drugs (11/12 paroxysmal, 7/9 persistent, and 1/1 long-standing persistent). Three patients had a sternotomy because of uncontrolled bleeding during thoracoscopic surgery. Four adverse events were 1 hemothorax, 1 pneumothorax, and 2 pneumonia. No thromboembolic complications or mortality occurred. CONCLUSIONS: Thoracoscopic surgery with PVI and ganglionated plexus ablation for AF is a safe and successful procedure with a single procedure success rate of 86% at 1 year. Electrophysiological guided thorough PVI and additional left atrial ablation line creation presumably contributes in achieving a high success rate in the surgical treatment of AF.
背景:胸腔镜肺静脉隔离(PVI)和神经节丛消融是治疗心房颤动(AF)的一种新方法。我们假设在随访中,对 PVI 结果进行细致的电生理确认会导致 AF 复发减少。
方法和结果:手术通过双侧 3 个端口进行。定位神经节丛,然后进行消融。进行 PVI 并确认入口和出口阻滞。对于非阵发性 AF 患者,创建额外的左心房消融线并验证传导阻滞。切除左心耳。通过每 3 个月进行心电图和 Holter 监测或在心律失常症状期间评估 AF 自由。在 3 个月后停用抗心律失常药物,并根据指南停用口服抗凝剂。31 例患者接受治疗(16 例阵发性 AF,13 例持续性 AF,2 例持久性 AF)。13 例非阵发性患者接受额外的左心房消融线治疗。1 年后,22 例患者中有 19 例(86%)无 AF、房扑或房性心动过速复发,且未使用抗心律失常药物(11/12 例阵发性,7/9 例持续性和 1/1 例持久性)。3 例患者因胸腔镜手术中无法控制的出血而进行了胸骨切开术。4 例不良事件为 1 例血胸、1 例气胸和 2 例肺炎。无血栓栓塞并发症或死亡。
结论:胸腔镜 PVI 和神经节丛消融治疗 AF 是一种安全有效的方法,1 年时单次手术成功率为 86%。电生理引导的彻底 PVI 和额外的左心房消融线创建可能有助于实现 AF 手术治疗的高成功率。
Circ Arrhythm Electrophysiol. 2008-10
J Thorac Cardiovasc Surg. 2012-11-2
Mol Ther Methods Clin Dev. 2025-7-15
Rev Cardiovasc Med. 2025-4-23
Cardiol Ther. 2024-9
Biology (Basel). 2024-2-7
Front Cardiovasc Med. 2023-3-10